Browse Studies — Arctuva

Phase 1

An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC)

This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell t…

Hepatocellular CarcinomaLiver Cancer, AdultLiver Neoplasm+1 more

Estimated

~$10 – $8,750

Eureka Therapeutics Inc.NCT04864054

Phase 1

An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)

Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET…

HepatoblastomaHepatocellular Carcinoma (HCC)Liver Neoplasms+3 more

Estimated

~$10 – $8,750

Eureka Therapeutics Inc.NCT04634357

Phase 2

A Pilot Study of 68Ga-PSMA-11 PET-directed Radioligand Therapy in Patients With Metastatic Hepatocellular Carcinoma (HCC)

The purpose of this study is to look at the effects (good and bad) of a drug called 177Lu-PSMA-617 (also known as the study drug) when given to participants wh…

Liver CancerHepatocellular CarcinomaMetastatic Liver Cancer

Estimated

~$10 – $7,500

Melissa LumishNCT06852820